# Evaluating Panitumumab (ABX-EGF) in Patients With Metastatic Colorectal Cancer

> **NCT00111761** · PHASE2 · COMPLETED · sponsor: **Amgen** · enrollment: 43 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** Irinotecan
- **BIOLOGICAL:** Panitumumab
- **DRUG:** 5-Fluorouracil
- **DRUG:** Leucovorin

## Key facts

- **NCT ID:** NCT00111761
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-07
- **Primary completion:** 2008-02
- **Final completion:** 2008-10
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2013-12-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00111761

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00111761, "Evaluating Panitumumab (ABX-EGF) in Patients With Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-07-31 from https://api.ai-analytics.org/clinical/NCT00111761. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*